thalidomide

GPTKB entity

Statements (52)
Predicate Object
gptkbp:instanceOf gptkb:chemical_compound
gptkb:drug
gptkbp:approvedBy FDA (for specific uses)
gptkbp:ATCCode L04AX02
gptkbp:CASNumber 50-35-1
gptkbp:category orphan drugs
immunosuppressants
sedatives
glutarimides
phthalimides
teratogens
gptkbp:chemicalFormula C13H10N2O4
gptkbp:contraindication pregnancy
gptkbp:developedBy gptkb:Chemie_Grünenthal
gptkbp:discoveredBy gptkb:Heinrich_Mückter
gptkbp:eliminationHalfLife 5-7 hours
gptkbp:hasEnantiomer gptkb:(R)-thalidomide
gptkb:(S)-thalidomide
https://www.w3.org/2000/01/rdf-schema#label thalidomide
gptkbp:introducedIn 1957
gptkbp:IUPACName 2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
gptkbp:legalStatus prescription only
restricted distribution
gptkbp:mechanismOfAction anti-inflammatory
anti-angiogenic
immunomodulatory
gptkbp:meltingPoint 270–272 °C
gptkbp:metabolism liver
gptkbp:molecularWeight 258.23 g/mol
gptkbp:notableFor gptkb:thalidomide_tragedy
causing birth defects in the 1950s and 1960s
gptkbp:pregnancyCategory X (contraindicated)
gptkbp:PubChem_CID CHEMBL651
5426
DB01041
gptkbp:relatedTo gptkb:lenalidomide
gptkb:pomalidomide
gptkbp:routeOfAdministration oral
gptkbp:sideEffect birth defects
constipation
peripheral neuropathy
rash
drowsiness
gptkbp:solubility slightly soluble in water
gptkbp:UNII 4Z8R6ORS6L
gptkbp:usedFor gptkb:erythema_nodosum_leprosum
multiple myeloma
leprosy
HIV-associated wasting
gptkbp:withdrawn many countries
gptkbp:bfsParent gptkb:Celgene
gptkbp:bfsLayer 6